Last reviewed · How we verify
HBV vaccination
HBV vaccination stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus antigens, preventing infection and chronic disease.
HBV vaccination stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus antigens, preventing infection and chronic disease. Used for Prevention of hepatitis B virus infection in infants, children, and adults, Post-exposure prophylaxis in non-immune individuals exposed to HBV.
At a glance
| Generic name | HBV vaccination |
|---|---|
| Also known as | Euvax B Inj |
| Sponsor | Seoul National University Hospital |
| Drug class | vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains hepatitis B surface antigen (HBsAg), typically produced via recombinant DNA technology, which triggers both humoral (antibody) and cell-mediated immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of the virus upon exposure, preventing establishment of infection and chronic hepatitis B.
Approved indications
- Prevention of hepatitis B virus infection in infants, children, and adults
- Post-exposure prophylaxis in non-immune individuals exposed to HBV
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue or malaise
- Headache
- Myalgia
Key clinical trials
- INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit (NA)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. (PHASE4)
- Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children (PHASE4)
- Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol (NA)
- RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
- Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |